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Abstract
Most persons in drug treatment smoke cigarettes. Until drug treatment facilities systematically
treat their patients' tobacco use, millions will flow through the drug treatment system, overcome
their primary drug of abuse, but die prematurely from tobacco-related illnesses. This paper reviews
the literature on the health benefits of quitting smoking for drug treatment patients, whether
smoking causes relapse to other drug or alcohol abuse, the treatment of tobacco dependence, and
good and bad times for quitting smoking among drug treatment patients. It also presents a
conceptual model and recommendations for treating tobacco in substance abuse treatment, and
provides references to internet and paper-copy tools and information for treating tobacco
dependence. At present, research on tobacco treatment in drug treatment is in its infancy.
Although few drug treatment programs currently offer formal services, many more will likely begin
to treat nicotine dependence as external forces and patient demand for these services increases.
In the absence of clear guidelines and attention to quality of care, drug treatment programs may
adopt smoking cessation services based on cost, convenience, or selection criteria other than
efficacy. Because research in this field is relatively new, substance abuse treatment professionals
should adhere to the standards of care for the general population, but be prepared to update their
practices with emerging interventions that have proven to be effective for patients in drug
treatment.
Review
Tobacco dependence among drug treatment patients is 
prevalent and deadly
Globally, millions of people have alcohol and illicit drug
use disorders [1,2]. In the U.S. alone, over a million peo-
ple receive treatment for drug misuse annually [3].
Although no strong population-based data are available,
rates of smoking reported in various drug treatment set-
tings range from 93% among outpatient methadone
patients in the U.K., to 90% among alcoholic inpatients in
the U.S., to 83% among urban methadone maintenance
patients in the Northeastern U.S., to 77% among metha-
done maintenance patients in the Midwestern U.S [4-7].
Until drug treatment facilities systematically treat their
patients' tobacco use, millions will flow through the drug
treatment system, overcome their primary drug of abuse,
but die prematurely from tobacco-related illnesses. For
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example, among 550 methadone patients in a U.S. Mid-
west city, the cigarette smoking prevalence rate was 74%
even though they had been in treatment an average of 10
years [5]. Current and former smokers from this pool of
drug-using patients attributed a number of health and
safety problems to their tobacco use, including emphy-
sema and bronchitis, not having enough stamina for work
or children, slower recovery from illness, and house fires
[8]. Longitudinal research bears this out: a 3-year longitu-
dinal study of 254 poly-drug users in treatment found that
rates of disability were significantly higher among smok-
ers than nonsmokers [9].
Although few data are available, it is likely that drug users
in recovery experience devastatingly high rates of tobacco-
related deaths. In an 11-year retrospective cohort study of
845 persons who had been in addictions treatment, Hurt
and colleagues [10] found that 51% of deaths were due to
tobacco-related causes. This high rate of tobacco-related
mortality is twice that expected in the general population.
Likewise, Hser and colleagues [11] found that cigarette
smoking contributes to mortality above and beyond
deaths due to opiate use; in their 24-year follow-up of
drug users that were admitted to drug treatment in 1964,
the death rates of smokers were four times that of non-
smokers.
Will drug treatment patients who quit live longer, healthier 
lives?
One in two long-term smokers will die of a tobacco-
related illness [12]. Within the general population, people
who stop smoking, even at the age of 40 or 50, avoid more
than 90% of the lung cancer risk associated with tobacco
[13]. Quitting smoking immediately reduces risks for car-
diovascular disease and cancer; it also reduces risks for
low birth weight, respiratory illness, and sudden infant
death syndrome among the children of smokers [14]. Few
data are available on the health effects of quitting smok-
ing specific to drug users in recovery, but drug treatment
patients who quit smoking have been shown to improve
their quality of life [9]. Regardless of their age, drug treat-
ment patients will probably live longer if they quit. People
who stop smoking at the age of 35 gain an estimated 6.1–
8.5 years of life; those who quit at the age of 65 live 1.4–
3.7 years longer than if they had not quit [15].
Most drug treatment patients who quit smoking do not 
relapse to other drug abuse
Drug treatment patients who are able to quit smoking, or
who participate in smoking cessation interventions, on
average do not relapse but actually have better drug treat-
ment outcomes. Several studies have found that tobacco
abstinence correlates to drug abstinence. Lemon and col-
leagues, [16] in a retrospective study of 2,316 clients
enrolled in the U.S. Drug Abuse Treatment Outcomes
Study, found that smoking cessation was associated with
drug abstinence one year following admission for drug
abuse treatment. In another longitudinal study [17] of
poly-drug users, drug-positive urine tests among stable
smokers were 2–5 times more frequent than drug-positive
urine tests among stable non-smokers at all three annual
assessment points. In a recent randomized controlled trial
of a smoking cessation intervention among methadone
patients, patients provided significantly more opiate and
cocaine-positive urine tests during times they were smok-
ing cigarettes than when they were tobacco-abstinent [18].
These findings suggest that abstaining from smoking
doesn't automatically throw patients into relapse, but
they may also be due to self selection – i.e., individual
patients who are able to quit smoking are also better able
to cope with their other addictions.
A cluster-randomized trial of a smoking cessation inter-
vention among patients with alcoholism offers stronger
evidence that treating smoking does not cause relapse.
Twelve residential treatment centers in the Midwest were
matched and randomly assigned to intervention or con-
trol conditions. The intervention condition consisted of
one pre-discharge individual counseling session delivered
by site staff, and 3 post-discharge counseling sessions
delivered by research staff over the phone. Pharmacother-
apy for nicotine dependence was not provided to any par-
ticipants. Participants in the control group received usual
care. The intervention was ineffective for smoking cessa-
tion: participants in the intervention group were no more
likely than participants at control sites to be abstinent
from smoking 6 or 12 months after the intervention. More
importantly, at both follow-up points, participants at
intervention sites were significantly more likely to be
abstinent from alcohol than control site participants [19].
Hence, the quit smoking intervention did not undermine,
but actually promoted, alcohol abstinence.
However, a subset of people in recovery may be at
increased risk for relapse when trying to quit. During the
course of another smoking cessation trial among 300 per-
sons recruited from the general community, 9 participants
developed such severe psychiatric problems that they were
advised to resume smoking [20]. Eight of these partici-
pants had a history of depression. There is no way to know
how many of these participants would have developed
these problems during this time even if they had not been
in the trial. Given the prevalence of diagnosed and, more
importantly, undiagnosed depression [21], monitoring
drug treatment patients for depression and relapse to drug
abuse during tobacco quit attempts is warranted.
Taken together, studies on drug relapse and smoking ces-
sation suggest that most drug treatment patients will ben-
efit from trying to quit smoking; most will not relapse toSubstance Abuse Treatment, Prevention, and Policy 2006, 1:23 http://www.substanceabusepolicy.com/content/1/1/23
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drug abuse as a result; a very small percentage may be at
risk for developing either depressive symptoms or drug
relapse when trying to quit; and that, during smoking ces-
sation attempts, close monitoring of patients for emergent
symptoms of mental illness is crucial.
Drug treatment patients are willing and able to quit 
smoking
Recent studies suggest that drug treatment patients are
interested in quitting smoking, have tried to quit repeat-
edly, and often have made a serious attempt to quit within
the last year [22-26]. For example, two separate regional
surveys in U.S. methadone maintenance clinics found that
most patients (70%–80%) were either somewhat or very
interested in quitting and that most (68%–75%) had tried
to quit at least once in their lives [5,7] One of these studies
examined readiness to change and found that nearly half
(48%) of respondents were currently contemplating quit-
ting and another 22% were preparing to quit [7]. In a sep-
arate study, 40% of clients for whom heroin was the drug
of choice indicated they were interested in stopping smok-
ing when they presented for treatment [25].
Epidemiological studies find that people with former and
current substance abuse problems can quit smoking. Peo-
ple with a past history of alcohol problems achieve the
same quit rates as people with no history of alcohol prob-
lems [27]. In a national sample of 1,465 active illicit drug
users in the U.S., 1 in 5 (21%) were former smokers [28].
Two separate regional surveys found that sizable minori-
ties of methadone patients (11%–12%) were former
smokers [5,7]. Although the quit rates among drug users
are low compared to quit rates in the general population
or among alcohol users, there are substantial data show-
ing that substance abuse patients can indeed quit smok-
ing. The question that remains is how best to help even
more substances abusers achieve lasting abstinence.
Substance abuse treatment community response
Some substance abuse treatment facilities are beginning
to treat nicotine dependence. In 1998, the SAMHSA Uni-
form Facility Data Set found 1 in 5 substance abuse treat-
ment facilities offered some form of smoking cessation
services [29]. A more recent (2001) survey of Canadian
drug abuse treatment facilities found that 54% reported
they offered clients help quitting smoking, but only 10%
had any formal group or individual therapy dedicated to
smoking cessation, and fewer than 1% of facilities offered
nicotine replacement or bupropion [30]. A survey of U.S.
methadone facilities found that many clinics had pro-
vided the following services to at least one patient in the
past month: 73% provided brief advice to quit, 18%
offered quit smoking classes/groups, and 12% prescribed
nicotine replacement [31]. However, among methadone
clinics that had provided service to anyone in the past
month, the median number of patients served was small,
ranging from 3–20 even though the average clinic size was
229 patients, most of whom smoked. This survey also
found that most methadone clinics ban indoor smoking
but many allow smoking outdoors, which might send
mixed signals to patients regarding the clinic's commit-
ment to treating smoking [32]. A small but significant
minority of providers (25%) had discouraged patients
from trying to quit smoking [33]. These data suggest that
methadone clinics are beginning to address smoking, but
that treatment for nicotine dependence is far from rou-
tine, few methadone clinics offer standard of care, many
have policies that allow outdoor smoking which may
undermine treatment, and some actively discourage quit
attempts.
How is tobacco dependence treated?
Effective tobacco treatment is evidence-based and
includes office systems that ensure routine intervention
and follow-up. Nicotine dependence treatment for the
general population has been rigorously evaluated [34-36].
This research has to date focused on delivery of services in
medical care settings including outpatient primary care,
[37] specialty outpatient clinics, [38] and managed care
systems [39]. Based on these studies, the U.S. Public
Health Service Guideline recommends that: a) all smokers
be offered treatment, b) patients unwilling to quit be pro-
vided with a brief intervention to build motivation, and c)
patients willing to quit be offered evidence-based treat-
ment [34]. Office-based intervention should follow five
major steps (The "5 A's") to intervene systematically with
patients: Ask the patient if she or he uses tobacco; Advise
him or her to quit; Assess willingness to quit; Assist with
quit attempt; and Arrange  for follow-up to prevent/
address relapse. Model programs in large managed-care
organizations suggest that full implementation of the U.S.
PHS Guideline increases the use of proven treatments and
decreases smoking prevalence [40].
In the U.K., the National Institute for Health and Clinical
Excellence (NICE) offers similar guidelines, namely, that
all smokers be advised to quit, asked about their interest
in quitting, and clearly advised to quit [41]. Perhaps
because the U.K. National Health Service offers a univer-
sally-available intensive quit-smoking program, it is rec-
ommended that health care providers conduct brief
interventions with patients, and then offer patients refer-
rals to more intensive support services. Providers who
have been trained as National Health Service stop smok-
ing counselors may 'refer' patients to themselves where
appropriate.
Pharmacotherapy for smoking cessation consists of 7 first-
line medications: bupropion SR, varenicline, and five
forms of nicotine replacement therapy (NRT; patch, gum,Substance Abuse Treatment, Prevention, and Policy 2006, 1:23 http://www.substanceabusepolicy.com/content/1/1/23
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lozenge, nasal spray, and inhaler). All have been approved
for use in treating smoking cessation by the U.S. Food and
Drug Administration. Six are recommended for smoking
cessation by the National Institute for Clinical Excellence
(NICE) in the U.K. The newest, varenicline, is undergoing
NICE appraisal for clinical and cost effectiveness. Bupro-
pion and NRT increase the odds of quitting 1.5 to 2 fold
over counseling alone [42]. Because bupropion and NRT
are equally effective, the choice of which product to use
should be guided by patient preferences and the product's
adverse effect profile [43]. Excellent descriptions of con-
traindications, side effects, dosage, duration, and availa-
bility of NRT and bupropion are available from several
internet sources [44,45].
Bupropion and NRT are more effective than using no
medication to quit, but 4/5 of smokers that use any of
these medications to quit will return to smoking within a
year [46]. A 12-week course of varenicline (2 mg per day)
was shown to be more effective for smoking cessation
than 12 weeks of bupropion (300 mg per day) in one clin-
ical trial [47]. Two trials that compared daily doses of 300
mg versus 150 mg bupropion for smoking cessation
found significantly higher quit rates for 300 mg at end of
treatment. Quit rates for the 300 mg dose remained higher
but were not significantly different than quit rates for the
150 mg dose at 12 months [48,49]. Varenicline has fewer
side effects and contraindications than bupropion, but
has not been tested among people in recovery. Bupropion
has been shown to be effective for smoking cessation
among people with a history of alcoholism [50], and in
conjunction with NRT is a promising cessation regimen
for methadone patients [51]. Bupropion is also an antide-
pressant, although its efficacy for smoking cessation is
independent of history of depression [50] and is not due
to diminished post-cessation depression [52]. However,
bupropion may confer some beneficial side effects on
depressive symptoms among drug treatment patients,
who experience higher rates of depression and depressive
symptoms than found in the general population [53].
Patients experiencing adverse side effects at 300 mg can try
the lower dose, which is associated with fewer adverse
effects and similar quit rates at 12 months. Hence, even
though varenicline is newer, potentially more effective for
smoking cessation, and has fewer contraindications,
bupropion remains an important option for many drug
treatment patients because it is less expensive and may
confer ancillary mental health benefits.
Behavioral treatment for nicotine dependence typically
consists of group or individual counseling and pharmaco-
therapy. Counseling of greater than 10 minutes produces
significantly greater cessation rates when compared to no-
contact interventions – at least 4 sessions are recom-
mended [34]. Medications, including bupropion and nic-
otine replacement therapies, double quit rates when
compared to placebo [43,45]. The highest abstinence rates
are achieved when pharmacotherapy is combined with
intensive counseling [54].
Government guidelines also recommend office-based sys-
tems to identify, track, and follow-up with smokers at
every visit and remind providers to intervene [34,41].
Without these systems, providers' practices do not change,
even when they have participated in training [55,56].
Do smoking cessation interventions for alcohol and drug 
treatment patients work?
A number of studies suggest that nicotine dependence
treatment can be effective for addictions patients. Studies
conducted in alcohol treatment achieved moderate but
significant long-term success. Two definitive trials in the
U.S. provided patients in treatment for alcohol depend-
ence with nicotine replacement therapy and counseling,
and achieved 12-month quit rates of 12% [57,58].
Smoking cessation treatment studies among people in
recovery from illicit drug use have achieved impressive
quit rates during the intervention, but modest long term
outcomes. In two small trials that did not use pharmaco-
therapy, all patients relapsed at the end of treatment
[59,60]. In an uncontrolled trial among 40 patients given
10 weeks of nicotine patches and counseling, 30% of
patients at week 4 and 7% at week 12 were tobacco absti-
nent [61]. The two large-scale trials (N = 383; N = 175)
that have been conducted to date compared less intensive
to more intensive behavioral therapies, with all partici-
pants receiving nicotine patches. These trials, which were
both conducted among methadone patients, achieved
high rates of both setting a quit date (81%) and absti-
nence (36%) during treatment. Following treatment,
however, most participants quickly relapsed to smoking.
At 6–12 months post-intervention, neither trial found sig-
nificant differences between groups, and across groups
abstinence rates were only 5–7% [18,62]. A recent pilot
study of an intensive intervention (7 weeks of bupropion,
12 weeks of nicotine gum, and 6 sessions of Motivational
Interviewing-based counseling) among 28 methadone
patients achieved a quit rate of 14% at 6 months [51].
Patients with co-occurring substance abuse and mental ill-
ness warrant heightened surveillance. One study found
that smokers with a history of major depression who
abstained from smoking were at higher risk of a new
major depressive episode than persons with a similar his-
tory who continued to smoke [63]. Given the very strong
associations between substance abuse and major depres-
sion in the general population [64], it is important to
screen smoking cessation candidates for history of major
depression prior to quit attempts, consider proactivelySubstance Abuse Treatment, Prevention, and Policy 2006, 1:23 http://www.substanceabusepolicy.com/content/1/1/23
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treating persons with a positive history of major depres-
sion, and monitor for emergent symptoms during smok-
ing cessation attempts. Substance abuse patients with co-
occurring mental illness that wish to quit smoking should
be medically evaluated and followed, preferably by a psy-
chiatrist.
When is it inadvisable to quit smoking?
To date, few studies have addressed whether there are
times or situations during which it is inadvisable for drug
treatment patients to quit smoking, but the timing of
smoking cessation intervention may be important. One
trial compared tobacco treatment immediately versus
tobacco treatment 6 months after admission to drug treat-
ment [65]. All patients who indicated they were ready to
quit smoking received free nicotine replacement therapy.
Both groups had equivalent smoking cessation rates, but
the group that started smoking cessation treatment on
admission had higher rates of alcohol relapse. However,
this study did not include a no-treatment control arm to
assess alcohol relapse rates among patients receiving no
tobacco treatment. Nonetheless, this study suggests that
delaying treatment until patients are stable in recovery,
perhaps as long as 6 months, may be better for some
patients. The one other trial (N = 36) that specifically
examined the timing of tobacco treatment in this popula-
tion found that timing did not significantly impact smok-
ing or alcohol use outcomes [66]. Additional studies
examining the impact of concurrent versus delayed nico-
tine dependence treatment for patients entering substance
abuse treatment should be conducted before completely
rejecting concurrent treatment [67].
In another study, 408 U.S. methadone treatment provid-
ers were surveyed about good and bad times for quitting
smoking [33]. Most (38%) clinic leaders thought the best
time to treat patients for nicotine dependence was when-
ever the patient wanted treatment. One in four clinic lead-
ers reported they or one of their staff had ever advised a
patient to delay quitting smoking cigarettes. Some reasons
for advising delay were: a) alcohol and illicit drug use are
the treatment priority, b) patients should not change too
many things at one time, c) patients were new to drug
treatment, d) patients were experiencing stress, and e)
patients were reducing their methadone dose or were
"detoxing" to end treatment.
Treating tobacco dependence in drug treatment patients is
warranted. Smoking is so deadly, and so many people in
drug treatment smoke, that even low rates of cessation
will achieve significant improvements in the health of
drug users. Tobacco treatment may also improve drug
treatment outcomes, regardless of whether patients suc-
cessfully quit smoking on any one quit attempt. The fact
that smoking cessation trials among illicit drug users
achieved respectable within-treatment quit rates, but that
most patients resumed smoking at the end of treatment,
suggests that short term counseling and pharmacotherapy
work. However, this approach may not be sufficient for
long-term success among drug users. Dual pharmacother-
apy and intensive counseling may be more effective, but
more research is needed to determine how best to treat
nicotine dependence among drug users.
Implications for delivering high-quality tobacco treatment 
to drug treatment patients
These studies highlight aspects of treatment that are
important for drug treatment patients. It may be best to
delay treating patients for tobacco dependence until they
have finished induction into drug treatment, perhaps
even 6 months of drug treatment [68]. It is important to
discuss past experiences with quitting with patients, to
assess whether they had emergent symptoms of mental ill-
ness or drug relapse during prior quit attempts. During
treatment for nicotine dependence patients should be
monitored frequently for early symptoms of relapse or
mental illness, and clinicians may consider proactively
treating such symptoms before a tobacco quit attempt
[57]. Drug treatment facilities should avoid undermining
quit attempts through smoking policies that send mixed
messages, or through staff that discourage patients from
trying to quit. Pharmacotherapy is crucial to effective
tobacco treatment. Lastly, drug treatment patients may
require more intensive, longer-term treatment for nicotine
dependence to achieve long term tobacco abstinence. We
do not know of studies that provide evidence that smok-
ing cessation is contraindicated for any specific groups of
drug treatment patients. This may, unfortunately, be due
to a lack of studies on this important topic. Future
research should be conducted to understand the impact of
smoking, identify better cessation methods, and identify
the beneficial and adverse effects of quitting smoking
within this population.
Conclusion
Conceptual model and recommendations for treating 
tobacco in substance abuse treatment
A working model (Figure 1) depicts the program
attributes and specific interventions that current research
suggests will contribute to high-quality tobacco treatment
in drug treatment facilities. This model suggests program
elements that must be present at the program level to
effectively help patients quit smoking.
The program attributes are the four domains of organiza-
tional readiness proposed by Simpson et al.'s Texas Chris-
tian University Treatment Model [69]. In order to provide
high-quality services, facilities must have sufficient
resources, staff, climate, and readiness. Resources might
include office space, sources for referral, and treatmentSubstance Abuse Treatment, Prevention, and Policy 2006, 1:23 http://www.substanceabusepolicy.com/content/1/1/23
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materials. Staff includes staff time and training. Climate
includes favorable attitudes toward treating smoking.
Readiness includes motivation to treat smoking, as well as
willingness to change clinic infrastructure and practices to
provide optimal treatment.
The services that facilities provide should adhere to evi-
dence-based guidelines such as the U.S. PHS Guideline,
the U.K. NICE guideline, or other guidelines based on cur-
rent research. This model employs the 5 A's for treating
tobacco use, modified slightly to incorporate research
findings related to smoking cessation in addictions
patients. Providers should routinely ask about and update
patients' smoking status. Patients should routinely be
given clear and individualized advice  to quit smoking.
When  assessing  patients' interest in quitting, providers
should also document patient's history of mental illness
and discuss past quit attempts to assess whether patients
relapsed to drug use, felt they were at risk for relapsing, or
experienced depressive or other psychological symptoms.
Scales such as the CES-D are easily administered and
scored and are useful for tracking changes in depressive
symptoms [70]. Assistance  can consist of treatment or
referral. The University of Medicine and Dentistry of New
Jersey Tobacco Control Program offers a detailed, manu-
alized guide to treating tobacco dependence among drug
treatment patients that is based on U.S. PHS guidelines
[71]. Pharmacotherapy for nicotine dependence is
extremely important for drug treatment patients, as no tri-
als have achieved significant results without it. Providers
should arrange to follow up with patients on cessation
progress, regardless of whether the provider or a referral
agency provides treatment. If another provider delivers
treatment, arrangements should be made to transfer
reports to the addictions treatment provider. Among drug
treatment patients, there is a 6th "A" which stands for
Avoid. Although there may beconditions under which
drug treatment patients might be advised against trying to
quit smoking, drug treatment programs should adopt pol-
icies and practices that do not undermine patients' moti-
vation to quit or sabotage the programs' own smoking
cessation interventions.
Office systems that ensure adherence to these treatment
guidelines should be developed. Government guidelines
stress the importance of office systems for ensuring full
and routine implementation of tobacco treatment. Exam-
ples of such office supports include written policies and
protocols providing rationales and methods for interven-
tion, office forms documenting smoking status and treat-
ment progress, electronic or paper record prompts for
intervention and follow-up, routine distribution of self-
help materials to smokers, protocols for referring smokers
to tobacco treatment specialists outside the facility, proce-
dures for prescribing/obtaining pharmacotherapy for
smokers, and periodic record reviews to track facility per-
formance on tobacco treatment among patients [72].
We do not recommend that patients be required to quit
smoking, nor that substance abuse treatment be termi-
nated if patients continue to use tobacco. Tobacco use
should be treated as a chronic, relapsing condition similar
to other forms of drug abuse or other chronic health con-
ditions such as diabetes, asthma, and hypertension [73].
In this approach, the focus is on delivering evidence-based
care, monitoring progress, encouraging renewed quit
attempts when relapse occurs, and changing tactics if
progress is not satisfactory. In accordance with clinical
practice guidelines, substance abuse treatment facilities
should routinely assess patients' smoking status, routinely
assess readiness to quit, routinely offer assistance in quit-
ting smoking, and provide treatment to patients who are
ready to quit. Facilities that do not have the resources to
treat smoking may refer patients to quitlines or other
health care providers that do have specialized training in
tobacco treatment.
Program attributes, interventions, and office systems for treating tobacco in substance abuse treatment Figure 1
Program attributes, interventions, and office systems for treating tobacco in substance abuse treatment.
Quality of 
Care for 
Tobacco 
Dependence 
Program Attributes
Resources-staffing levels, funds, 
space, training resources 
Staff-smoking status, training, 
adaptability to new approaches
Climate-mission/goals related to 
tobacco & health, role overload, 
openness to change 
Readiness-perceived need and 
pressure to, treat smoking
ĺ
Program Interventions
Ask- identify smokers and record smoking status 
Advise- advise patients to quit 
Assess- readiness to quit, screen for past mood/anxiety 
disorders, discuss history of quit attempts, symptoms
Assist- patients to quit with group/individual counseling or 
classes, pharmacotherapy, referral to outside agency for 
treatment, proactive therapy for past major depression 
Arrange– follow up to monitor tobacco use, drug craving, 
depression/anxiety or other emergent symptoms 
Avoid- undermining quit attempts or interest in quitting 
ĺ
Office Systems
Records- Have place(s) to document 
smoking status/progress in clinical record  
Reminders- Use stickers, checklists, flow 
charts to ensure treatment/follow-up
Protocols- Provide written guides for how 
to treat tobacco dependence 
Policies- Have and enforce indoor/outdoor 
smoking rules for patients/staff 
Tools- Provide/facilitate access to 
pharmacotherapy, support, materials 
ĺSubstance Abuse Treatment, Prevention, and Policy 2006, 1:23 http://www.substanceabusepolicy.com/content/1/1/23
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These are recommendations for what substance abuse
treatment facilities should do in order to provide optimal,
evidence-based tobacco treatment. Exactly how they
achieve or approximate these standards will depend on
the resources available to the facility, the smoker, and
their community/country. For example, patients in the
U.S. and other countries without universal access to
health care may have difficulty obtaining quit smoking
pharmacotherapy. Many patients in such settings have no
health insurance for medications, and their treatment
facilities may receive their funding from block grants that
must cover the costs of all services. Some of these facilities
or patients might be able to access other sources of fund-
ing for pharmacotherapy, such as Medicaid (in states in
which Medicaid pays for smoking cessation pharmaco-
therapy). Other facilities might be able to help patients
gain access to medications through pharmaceutical drug
company medication assistance programs, but some facil-
ities may not be able to provide any access to pharmaco-
therapy. In other countries, facilities may not be able to
provide pharmacotherapy, but patients can readily
acquire medications through their health care providers.
Many countries, and a few U.S. States, deliver behavioral
intervention through referral to tobacco treatment special-
ists, who work with smokers in person or over the tele-
phone. In these situations, a dual approach might be most
appropriate, including a) training/motivating facilities to
refer patients and b) developing a cadre of tobacco treat-
ment specialists with expertise in substance abuse treat-
ment.
More and more facilities will begin treating nicotine 
dependence
Even in the absence of tailored treatments, or additional
resources, broader trends will likely create additional rea-
sons for treating tobacco dependence. Attitudes toward
nicotine dependence treatment among the staff of drug
abuse treatment programs appear to be changing; surveys
conducted in 1999 and 2000 find more staff support for
helping patients to quit smoking compared to surveys
conducted in the 1980s and early to mid 1990s [74]. In
the 1990s, changes in hospital tobacco policy, state laws,
and local ordinances required drug abuse treatment facil-
ities to restrict indoor smoking and may have spurred
some to begin treating tobacco use [75]. A similar trend is
happening in residential and outpatient substance abuse
treatment. For example, in New Jersey a state law, staff
training, and provision of NRT resulted in widespread
adoption of tobacco treatment in residential substance
abuse treatment facilities [76]. Disciplinary associations
of drug abuse treatment providers such as the American
Society for Addiction Medicine (ASAM) and the Associa-
tion for Drug Abuse Treatment Professionals (NADAAC)
now recommend incorporating tobacco treatment into
addictions treatment [77,78].
Adherence to standard of care is essential until optimal 
care is identified
Research on tobacco treatment in drug treatment is in its
infancy – the types of services currently offered have not
been well described, few treatment models have been
developed for drug users, and measures of services and
patient outcomes are lacking. Although it appears that few
drug treatment programs offer formal services, many
more will likely begin to treat nicotine dependence as
external forces and patient demand for these services
increases. In the absence of clear guidelines and attention
to quality of care, programs may adopt services based on
cost, convenience, or selection criteria other than efficacy,
similar to treatment choices following the introduction of
managed care in drug treatment in the U.S. in the 1990s
[79]. For example, 6% of U.S. methadone facilities offer
acupuncture for smoking cessation, even though it has
not been shown to be effective for helping people quit
smoking [75, 80]. Because research in this field is rela-
tively new, substance abuse treatment professionals
should adhere to the standards of care for the general pop-
ulation, but be prepared to update their practices with
new interventions, proven to be effective for those in drug
treatment, as they emerge [34]. The New Jersey initiative
suggests that a combination of policy change, free staff
training on evidence-based treatment, and governmental
provision of pharmacotherapy together can promote
widespread adoption of high-quality care [76].
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